Demodex blepharitis impacts an estimated 25 million people in the U.S., yet many have never heard of it. In partnership with Tarsus Pharmaceuticals, “CBS Mornings” explores the connection between eye health and overall well-being, and looks at the new FDA-approved drug XDEMVY used to help treat the disease. Sponsored by XDEMVY. Rx only. Visit XDEMVY.com and ask your doctor if XDEMVY is right for you. Yuna Rapoport, M.D. is a paid spokesperson for Tarsus Pharmaceuticals, Inc. The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis. Please see additional important safety information at and full prescribing information here and available at XDEMVY.com. XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.